Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
NIH/ NINDS, Washington Hospital, Suburban Hospital
mi
from
Bethesda, MD
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
NIH/ NINDS, Washington Hospital, Suburban Hospital
mi
from
Bethesda, MD
Click here to add this to my saved trials
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
Boston Med Ctr
mi
from
Boston, MA
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
Washington University School of Medicine and Barnes Jewish Hospital
mi
from
St. Louis, MO
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
Washington University School of Medicine and Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
University of Tennessee Health Science Center
mi
from
Memphis, TN
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
University of Tennessee Health Science Center
mi
from
Memphis, TN
Click here to add this to my saved trials
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
Seton/UT Southwestern Medical Center
mi
from
Austin, TX
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
Seton/UT Southwestern Medical Center
mi
from
Austin, TX
Click here to add this to my saved trials
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
Intermountain Healthcare
mi
from
Murray, UT
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
Intermountain Healthcare
mi
from
Murray, UT
Click here to add this to my saved trials
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated:  3/21/2016
University of Massachusetts
mi
from
Worcester, MA
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Status: Enrolling
Updated: 3/21/2016
University of Massachusetts
mi
from
Worcester, MA
Click here to add this to my saved trials
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study
Status: Enrolling
Updated:  3/21/2016
Neurologique Foundation, Inc.
mi
from
Ponte Vedra, FL
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study
Status: Enrolling
Updated: 3/21/2016
Neurologique Foundation, Inc.
mi
from
Ponte Vedra, FL
Click here to add this to my saved trials
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Downey, CA
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Downey, CA
Click here to add this to my saved trials
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Daytona Beach, FL
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Status: Enrolling
Updated:  3/21/2016
mi
from
Montreal,
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Status: Enrolling
Updated: 3/21/2016
mi
from
Montreal,
Click here to add this to my saved trials
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome
Status: Enrolling
Updated:  3/21/2016
Gillette Children's Specialty Healthcare
mi
from
St. Paul, MN
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome
Status: Enrolling
Updated: 3/21/2016
Gillette Children's Specialty Healthcare
mi
from
St. Paul, MN
Click here to add this to my saved trials
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome
Status: Enrolling
Updated:  3/21/2016
Baylor School of Medicine
mi
from
Houston, TX
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome
Status: Enrolling
Updated: 3/21/2016
Baylor School of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome
Status: Enrolling
Updated:  3/21/2016
University of Alabama
mi
from
Birmingham, AL
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome
Status: Enrolling
Updated: 3/21/2016
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Status: Enrolling
Updated:  3/21/2016
Diagnamics Inc.
mi
from
Encinitas, CA
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Status: Enrolling
Updated: 3/21/2016
Diagnamics Inc.
mi
from
Encinitas, CA
Click here to add this to my saved trials
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Status: Enrolling
Updated:  3/21/2016
University of Michigan Scleroderma Program - Division of Rheumatology/Dept. of Internal Medicine
mi
from
Ann Arbor, MI
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Status: Enrolling
Updated: 3/21/2016
University of Michigan Scleroderma Program - Division of Rheumatology/Dept. of Internal Medicine
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Status: Enrolling
Updated:  3/21/2016
Cleveland Clinic
mi
from
Cleveland, OH
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Status: Enrolling
Updated: 3/21/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Status: Enrolling
Updated:  3/21/2016
Scleroderma Research Center - University of Pittsburgh School of Medicine
mi
from
Pittsburgh, PA
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Status: Enrolling
Updated: 3/21/2016
Scleroderma Research Center - University of Pittsburgh School of Medicine
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Acupressure and Acupuncture as an Intervention With Children With Autism II
Investigating the Use of Acupressure and Acupuncture With Children With Autism II
Status: Enrolling
Updated:  3/21/2016
Kennedy Krieger Institute
mi
from
Baltimore, MD
Acupressure and Acupuncture as an Intervention With Children With Autism II
Investigating the Use of Acupressure and Acupuncture With Children With Autism II
Status: Enrolling
Updated: 3/21/2016
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigative Site
mi
from
Englewood, CO
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigative Site
mi
from
Englewood, CO
Click here to add this to my saved trials
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigative Site
mi
from
Kansas City, KA
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigative Site
mi
from
Kansas City, KA
Click here to add this to my saved trials
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigator Site
mi
from
Milwaukee, WI
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigator Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis investigative site
mi
from
Innsbruck,
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis investigative site
mi
from
Innsbruck,
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated:  3/22/2016
UCSF Memory and Aging Center
mi
from
San Francisco, CA
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated: 3/22/2016
UCSF Memory and Aging Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated:  3/22/2016
Compass Research LLC
mi
from
Orlando, FL
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated: 3/22/2016
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated:  3/22/2016
Massachusetts General Hospital
mi
from
Boston, MA
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated: 3/22/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated:  3/22/2016
The Mayo Clinic
mi
from
Rochester, MN
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated: 3/22/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated:  3/22/2016
Perelman School of Medicine, University of Pennsylvania
mi
from
Philadelphia, PA
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated: 3/22/2016
Perelman School of Medicine, University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated:  3/22/2016
University Hospitals Leuven
mi
from
Leuven,
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Status: Enrolling
Updated: 3/22/2016
University Hospitals Leuven
mi
from
Leuven,
Click here to add this to my saved trials
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Status: Enrolling
Updated:  3/22/2016
Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital
mi
from
Hartford, CT
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Status: Enrolling
Updated: 3/22/2016
Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
An Eight-Week, Open Trial Pilot Investigation of Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  3/23/2016
UCLA
mi
from
Los Angeles, CA
Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
An Eight-Week, Open Trial Pilot Investigation of Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 3/23/2016
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy
Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  3/23/2016
Children's Hospital Boston
mi
from
Boston, MA
Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy
Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 3/23/2016
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury
Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury
Status: Enrolling
Updated:  3/24/2016
North Florida/South Georgia Veterans Health System, Gainesville, FL
mi
from
Gainesville, FL
Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury
Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury
Status: Enrolling
Updated: 3/24/2016
North Florida/South Georgia Veterans Health System, Gainesville, FL
mi
from
Gainesville, FL
Click here to add this to my saved trials
Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury
Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury
Status: Enrolling
Updated:  3/24/2016
James A. Haley Veterans' Hospital, Tampa, FL
mi
from
Tampa, FL
Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury
Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury
Status: Enrolling
Updated: 3/24/2016
James A. Haley Veterans' Hospital, Tampa, FL
mi
from
Tampa, FL
Click here to add this to my saved trials
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments
Status: Enrolling
Updated:  3/24/2016
OptumInsight Life Sciences
mi
from
Waltham, MA
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments
Status: Enrolling
Updated: 3/24/2016
OptumInsight Life Sciences
mi
from
Waltham, MA
Click here to add this to my saved trials
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Status: Enrolling
Updated:  3/25/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Status: Enrolling
Updated: 3/25/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Developing and Testing a Comprehensive MS Spasticity Management Program
Developing and Testing a Comprehensive MS Spasticity Management Program
Status: Enrolling
Updated:  3/25/2016
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Developing and Testing a Comprehensive MS Spasticity Management Program
Developing and Testing a Comprehensive MS Spasticity Management Program
Status: Enrolling
Updated: 3/25/2016
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  3/28/2016
Cleveland Clinic Mellen Center
mi
from
Cleveland, OH
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 3/28/2016
Cleveland Clinic Mellen Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Omalizumab in the Treatment of Peanut Allergy
Effects of Omalizumab on Peanut Allergen Induced Cellular and Clinical Responses in Peanut Allergic Adults
Status: Enrolling
Updated:  3/28/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Omalizumab in the Treatment of Peanut Allergy
Effects of Omalizumab on Peanut Allergen Induced Cellular and Clinical Responses in Peanut Allergic Adults
Status: Enrolling
Updated: 3/28/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
Status: Enrolling
Updated:  3/28/2016
Johns Hopkins University
mi
from
Baltimore, MD
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
Status: Enrolling
Updated: 3/28/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
Brookline Nursing & Rehabilitation Center
mi
from
State College, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
Brookline Nursing & Rehabilitation Center
mi
from
State College, PA
Click here to add this to my saved trials
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
Centre Crest Nursing Home
mi
from
Bellefonte, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
Centre Crest Nursing Home
mi
from
Bellefonte, PA
Click here to add this to my saved trials
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
Hearthside Nursing and Rehabilitation Center
mi
from
State College, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
Hearthside Nursing and Rehabilitation Center
mi
from
State College, PA
Click here to add this to my saved trials
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
Hearthside Nursing Home
mi
from
State College, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
Hearthside Nursing Home
mi
from
State College, PA
Click here to add this to my saved trials
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
Mountain View
mi
from
Scranton, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
Mountain View
mi
from
Scranton, PA
Click here to add this to my saved trials
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
Spring Creek Rehabilitation and Nursing Center
mi
from
Harrisburg, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
Spring Creek Rehabilitation and Nursing Center
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
The Meadows Manor
mi
from
Dallas, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
The Meadows Manor
mi
from
Dallas, PA
Click here to add this to my saved trials
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
The Village at Penn State
mi
from
State College, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
The Village at Penn State
mi
from
State College, PA
Click here to add this to my saved trials